April 2018

Platelets: Tips for Inventory Management in Shortages (Platelet TIMS)

By: Allison Collins MD FRCPC, ORBCoN Physician Clinical Coordinator

As part of the preparation for the upcoming blood shortage simulation exercise in Ontario, a document was prepared to assist hospitals in managing their platelet inventories in times of shortage. The full Tips for Inventory Management in Shortages (TIMS) document, including references, is available at: http://transfusionontario.org/en/download/platelet-tips-for-inventory-management-in-shortages-tims/. A summary is presented here.

 

Although transfusion of ABO identical platelets is the preferred approach, this may not be possible during shortages. Transfusion of cellular-incompatible platelets (a major mismatch) or plasma-incompatible platelets (a minor mismatch) may be necessary. In a cellular-incompatible transfusion, the donor platelets exhibit antigens not present in the recipient (e.g. group A platelets to a group O recipient). This may result in a decreased post-transfusion platelet count increment.

 

In a plasma-incompatible transfusion, the donor plasma contains antibodies to antigens present on the recipient’s red cells, which may lead to hemolysis in the recipient. Hemolysis is more likely if group O platelets containing high titre anti-A or anti-B are transfused into a non-group O recipient. For this reason, titres of anti-A and anti-B can be performed on group O platelets, and high titre components reserved for group O recipients. A method for performing titres is provided in the full Platelet TIMS document. It has been argued that asking for a ‘boutique’ inventory of group A platelets only, instead of performing titres on group O platelets, defers the burden of testing to sites which do accept group O platelets and perform titres on them (whether or not there is a platelet shortage). This approach should be avoided. Other options for managing unavoidable plasma-incompatible transfusions include limiting the volume of incompatible plasma transfused per 24 hour period, and volume-reducing the component.

 

If D positive platelets must be transfused to a D negative female of childbearing potential, Rh immune globulin (RhIG) prophylaxis should be administered. One 300µg dose of RhIG will cover multiple platelet transfusions for four weeks. RhIG prophylaxis is not required for males, or for females outside of their child bearing potential years (e.g. over the age of 45).

 

In times of platelet shortage, splitting of doses is an option for hospitals with the appropriate equipment and expertise. Lowering the platelet count threshold for prophylactic platelet transfusions should be considered, and recommended threshold adjustments are included in the Ontario Contingency Plan as Appendix F. Extension of platelet shelf life should only be considered if authorised by the National Advisory Committee on Blood and Blood Products (NAC) and/or the National Emergency Blood Management Committee (NEBMC).

 

Interested readers are referred to the Ontario Contingency Plan and the full Platelet TIMS document at http://transfusionontario.org/en/documents/?cat=emergency_blood.

 

 

 

2018 Ontario Blood Shortage Simulation Exercise – Question & Answers from the Orientation Webinar Sessions

By: Wendy Owens, ORBCoN; Dr. Allison Collins, ORBCoN; Helen Cheng, MOHLTC; Esther Sok, MOHLTC; Leonard Chu, MOHLTC; Lisa St-Croix, CBS

In February of this year, ORBCoN held a series of five webinars to provide information to hospitals preparing to participate in the planned provincial blood shortage exercise. The exercise, originally planned for the week of March 5th had to be deferred due to actual low inventory levels of red blood cells at Canadian Blood Services. The exercise will be re-scheduled and hospitals will all be notified as soon as the new date is chosen. In the meantime, we wanted to share with you, the questions that came up during the orientation webinars and the answers that were provided.

 

1. Question: Who will receive the notification during the exercise and will this be the same as for a real blood shortage situation?

 

Answer: The first notification a hospital would receive of a blood shortage will be through a fax sent to the fax number on file at CBS. These fax numbers are programmed into the sending fax machine. This notification would be completed in the same way in an exercise as for a real situation. Email notification to hospitals would be the secondary communication. This email would be sent to Transfusion Medicine Laboratory primary and secondary contacts on the CBS hospital contact list.

2. Question: Who should attend the CBS teleconference calls?

 

Answer: A point person in the Transfusion Medical Laboratory (TML) should attend these calls. This person can then share updates with others in the TML and with the Hospital Emergency Blood Management Committee (HEBMC). This should be covered in the Hospital Emergency Blood Management Plan.

3. Question: Could decisions around triage of blood orders for this exercise be made retrospectively as opposed to in ‘real time’ so as to better manage the workload and not impact patient care?

 

Answer: Yes. Hospitals can make and document their simulation decisions and actions retrospectively. Hospitals can participate in the exercise in a way to accommodate workload. For example, triage decisions may be made in a less rigorous manner for the exercise to simplify the process.

 

It would be helpful to clarify what process would be used if decisions were being made in a real blood shortage to ensure that those involved understand the different or abbreviated approach taken for the exercise.

4. Question: Can the post exercise survey questions be sent to hospitals prior to the simulation exercise?

 

Answer: The purpose of the exercise is to test existing communications and processes in the event of a real blood shortage situation. Providing surveys ahead of the exercise may unduly influence behaviour and answers received. The post-survey questions are consistent with the Ontario Contingency Plan for the Management of Blood Shortages. Therefore, the survey questions will not be sent out prior to the exercise.

5. Question: Can hospitals receive a copy of their own responses to the post exercise survey to keep on file?

 

Answer: Yes, this can be provided for hospitals once the report has been completed.

6. Question: The Ontario Contingency Planning toolkit mentions that autologous donation might be considered if there is a prolonged Amber phase or if there is a Red phase shortage. Would this actually still be an option?

 

Answer: Yes, autologous donation was left in as a consideration if the regular blood supply is limited. For elective surgeries, if the patient’s surgery may otherwise be delayed for an extended period, autologous donation may be one option, albeit likely not the first one. It might be a better option to try to optimize the patient’s hemoglobin prior to surgery to reduce the likelihood that they would need transfusion at all depending on the type of surgery they are having. Any alternatives to transfusion in general will need to be considered carefully during an actual blood shortage. Pre-autologous donation for surgery is no longer a recommended strategy for patients without rare blood types; however, in exceptional circumstances, it can still be an option.

7. Question: How will the Emergency Management Communication Tool (EMCT) inform users during the mock exercise?

 

Answer: EMCT is an Incident Management System-based tool that does not depend on knowing specific individuals’ email addresses. Incident tickets will be created on the EMCT test site for text messages. Users will receive automatic notifications via email and/or text message. Users may then log into the EMCT to view information on a dashboard display. Both tickets and dashboard will inform users about the exercise, and in a real blood shortage could inform about the status of any related information such as road closures or affected facilities or services across the province.

8. Question: What types of messages will be posted on EMCT for this exercise?

 

Answer: Because this is an interactive communication exercise, it is difficult to completely predict the content of messages. However, it is expected that the conversations will be high level and will relate to LHIN/regional concerns rather than detailed questions on products and services.

9. Question: Who should I inform if the hospital’s EMCT members list is outdated?

 

Answer: There is a one stop contact for all inquiries related to EMCT: EMCT@LHINS.on.ca

 

You can send an email to this address to remove old members and add new members. New members will be required to complete training modules, which take about an hour to complete, prior to being set-up in EMCT.

10. Question: Who at the hospital should be an EMCT user?

 

Answer: This could be, but not limited to: Executive personnel, Incident Management and Risk Management personnel and Operations emergency preparedness personnel. Most staff in hospital transfusion services would likely not need to register on EMCT. It would be the role of the registered EMCT users at each hospital to inform others within their facility of relevant information.

11. Question: Are there preventive measures for any misinterpretations of messages via EMCT? Is there a possibility that the exercise could be mistaken for a real situation?

 

Answer: There are two safeguards to help ensure this does not happen-
1. EMCT will be run on a TEST platform for this exercise
2. Standard practice requires EMCT to be prefaced by ‘EXERCISE EXERCISE’ or ‘SIMULATION SIMULATION’

12. Question: Would EMCT ever be used for CBS to notify hospitals of a blood shortage or to make decisions about allocation of blood?

 

Answer: No. This is not the intent or purpose of EMCT. CBS distributes blood in all provinces except Quebec. The EMCT is only an Ontario tool therefore, it would not be used to notify hospital transfusion services of important information. CBS does have users registered on the tool, however, they currently only have ‘observer status’. No clinical information is to be posted on EMCT for health information privacy therefore, it is not to be used for clinical management of patients. The purpose of using EMCT during this blood shortage exercise is to-
1. Raise awareness of the existence of the tool
2. Determine how the tool may be used for a blood shortage situation to help ensure rapid dissemination of information that may be helpful to decision makers.

13. Question: What should a hospital do if they have not registered on EMCT? Can they still participate in this Blood Shortage exercise?

 

Answer: The hospital can still participate in this blood shortage exercise in every other aspect than the EMCT portion. If a hospital still wants to register with EMCT, they can contact the email address mentioned above EMCT@LHINS.on.ca and request to be added on to the tool. New users are required to complete some training prior to being granted access to the tool.

If you have any additional questions about your contingency planning for blood shortages or the upcoming provincial blood shortage exercise, please do not hesitate to contact me at wowens@toh.ca.

 

March 2018

Transfusion of K negative RBC for Females of Child-bearing Potential

Authors:
D. Neurath, Manager, Transfusion Medicine, EORLA TOH sites
M. Tokessy, Change technologist, Transfusion Medicine, EORLA TOH General campus
H. Maddison Medical Technologist, Transfusion Medicine, EORLA TOH General campus
N. Cober Charge Technologist Transfusion Medicine, EORLA TOH Civic campus
S. Love Charge Technologist, Transfusion Medicine, EORLA TOH General campus
B. Ludington Medical Technologist Transfusion Medicine, EORLA TOH General campus

ABO and Rh(D) matching for red blood cell (RBC) transfusions is the standard of care to ensure safe blood transfusion and to circumvent alloimmunization to the D antigen. The prevention of Rh(D) alloimmunization is especially important for females of child bearing potential, in that maternal anti-D is known to cause hemolytic disease of the fetus and newborn (HDFN). Anti-K has been known to also cause severe HDFN. With no available prophylaxis, there is no protection for anti-K alloimmunization in pregnancies. While the incidence of K antigen is low, only 9%, its antigenic nature makes it a frequent antibody producer. Alloimmunization is mostly attributed to transfusion of K positive red blood cells (RBC). Selection of K negative RBC for blood transfusions to females of child-bearing potential will prevent development of anti-K in this vulnerable patient population.

 

A review was performed using the regular blood inventory to determine if sufficient number of K negative RBC units would be available for transfusions. It was determined that indeed we would have sufficient available inventory of K negative RBC for transfusions to female patients of child-bearing potential.

 

Each patient has a transfusion history check done prior to performing Type and Screen. All females identified as < 45 years old meet the criteria for selection of K negative RBC for blood transfusion to prevent alloimmunization. The existing inventory on hand is used without need for special requests from the Canadian Blood Services (CBS) for K negative RBC.

 

In May 2017 we implemented a process for all female patients of child-bearing potential to be transfused with K negative RBC. Between May 1, 2017 to December 31, 2017 there were 342 female patients in this category requiring blood transfusions of 1906 RBC units. The numbers include sickle cell exchanges; a total of 35 female patients requiring 721 RBC that were specifically requested from CBS for exchanges. Additionally, there were 13 patients requiring multiple transfusions, between 15 to 30 RBC units each. The K negative RBC inventory was most often sufficient and in-house phenotype was performed only when supply was depleted. The exception in this process occurs during a massive transfusion in which the critical situation does not allow it.

 

Considering the severity of hemolytic disease of the fetus and newborn due to anti-K and the readily available K negative RBC, we feel we are proactive in trying to eradicate anti-K alloimmunization by transfusion in the female population of child-bearing potential. The cost is negligible as the existing inventory of K typed RBC is mostly used.

 

What is the Canadian Obstetrical and Pediatric Transfusion Medicine Network (COPTN)?

Authors:
Gwen Clarke MD, Hematopathologist with Canadian Blood Services and Clinical Professor in the Department of Lab Med and Pathology at the University of Alberta
Lani Lieberman MD, Assistant Professor, University of Toronto and Transfusion Medicine Specialist, University Health Network and affiliated hospitals
Denise Evanovitch, ORBCoN Regional Manager, SW Ontario

The Canadian Obstetrical and Pediatric Transfusion Medicine Network (COPTN) is a subcommittee of the Canadian Society for Transfusion Medicine (CSTM) and was established in 2017. The membership consists of volunteer physicians, technologists and health care providers from across Canada with expertise in obstetrical and neonatal testing, transfusion and care. The subcommittee’s mandate is to assess, analyze and strive to implement best practices in pediatric and obstetrical transfusion practice in Canada. ORBCoN was invited to participate as a member of this group.

 

COPTN members frequently field obstetrical/neonatal questions from hospitals. Many of these issues are not included in transfusion and accreditation standards such as CSA, CSTM, IQMH and Accreditation Canada. Thus, there is a need for guidance on best practices in Canada for this patient group that is readily available for all pertinent specialties.

 

The COPTN’s objectives are to:

  • Survey practice related to pediatric and obstetrical laboratory testing and transfusion across various hospitals in Canada
  • Assess the literature regarding optimal transfusion practice and to share results with members
  • Discuss and develop national research projects in obstetrical and pediatric transfusion medicine
  • Develop best practice recommendations in pediatric and obstetrical transfusion practice
  • Serve as a forum to discuss challenging pediatric/obstetrical cases
  • Promote the safe use of blood products to pediatric and obstetrical patients

The first large scale initiative of COPTN is a Canada-wide survey of obstetrical and neonatal testing practices. It will be distributed to hospitals and other laboratories that conduct this type of testing (e.g. some Canadian Blood Services laboratories)and will be sent to participants in every province and territory. The purpose of the survey is to assess the current practice with regard to ABO, Rh, antibody screening, fetal-maternal hemorrhage assessment and RhIG administration. This analysis will provide a needs assessment of sorts to assist COPTN in prioritizing which guidance to develop first in order to provide the most benefit.

 

COPTN members developed the survey using the LimeSurvey® software and will be analyzing the results, which will be shared with the participating hospitals and laboratories. The survey does cover a large range of practice, so it is a longer one, but there is logic incorporated into the questions, so not all questions will require an answer from all respondents. It is divided into sections and you can stop and save your results at any time and continue completing the survey later. It will be distributed in the spring of 2018 and you will have six weeks to complete it. We would like a response from each hospital/laboratory. (rather than a single response from a health region).

 

We strongly encourage you to take the time to do this survey as the ultimate goal is to provide standardized, best care to obstetrical and neonatal patients throughout Canada. We look forward to your participation. Together, we can improve patient care across Canada.

 

 

 

February 2018

Blood transfusion camp: filling the gaps in medical education curriculum

By: Sasan Zandi, MD, PhD, Hematopathology resident, Laboratory medicine department, University of Toronto

Blood transfusion is one of the most commonly prescribed procedures by many disciplines in medicine and yet there is very little formal teaching in the existing medical education curriculum. In fact there are several studies in North America and Europe that report a high percentage of blood transfusions are inappropriate. Other studies have shown that a significant number of practicing physicians and residents are not able to obtain appropriate consent for transfusion mostly due to a knowledge gap or under- appreciation of the patient’s understanding and perception with regards to transfusion. Almost five years ago, a group of thoughtful and dedicated leaders in transfusion medicine recognized the deficiency in residents’ education and initiated a series of year-long transfusion workshops for the University of Toronto postgraduate students, dubbed as “Transfusion Camp”. This initiative soon drew the attention of the residents and the educators from other medical programs in Ontario and grew to a platform for teaching residents in various disciplines across the nation. The camp features University of Toronto educators in transfusion medicine who discuss the latest scientific findings in transfusion practice that have direct clinical impact on patient care.

 

I had the pleasure of participating in the 2017 transfusion camp with a group of friends and after spending a day in the camp, many of us realized that transfusion is not as simple of a procedure as we thought it was. We recognized that we all need to know a great deal more about the indications, appropriate choice of products, alternatives to transfusion and the side effects of transfusion in order to make the best possible decision for our patients. We all conceded that after the camp day, our practice and process of making decisions to transfuse blood and blood products and even the consent discussion would not be the same. Many of us felt that if we had this learning opportunity earlier we might have done things differently.

 

Another impressive fact about the transfusion camp apart from carefully selected content and objectives was the teaching model that was adapted. It is a combination of traditional didactic teaching and interactive learning formats that provides a forum to discuss various aspects of transfusion medicine and study real cases. The content of the lectures, videos and other educational material is also made publicly available to review prior to the course and to be used after the workshop as reference.

 

Witnessing the impact of the transfusion camp initiative in the daily practice of residents and subsequently improving the care we provide to patients, I think it is essential to include the transfusion education with the new camp format in the medical curriculum of all medical schools in Canada.

 

At the end I think it is incumbent upon me to recognize the tireless efforts of the extraordinary laboratory physicians Dr. Yulia Lin and Dr. Jeannie Callum who initiated this program and continue to strive to improve the quality of patient care by educating young physicians about transfusion.

“Hit the Repeat Button” How often is Antibody Identification required?

By Wendy Owens, ORBCoN Program Manager, NE Region

Antibody identification testing is initiated once a positive antibody screen test is detected. If a clinically significant antibody is identified, the result is reported and documented in the patient’s record. For patients who are chronic transfusion recipients, the question arises ‘Is it necessary to perform a full antibody identification each time that patient requires a crossmatch for transfusion?’

 

In 2017, ORBCoN performed a small ad hoc survey to ask hospitals in Ontario what their practice is with respect to repeat antibody identification testing. We received responses from 10 hospitals and they reported the following:

  • 1 hospital reported confirmation of the presence of the previously identified antibody and exclusion of new clinically significant antibodies using selected reagent red cells in addition to performing a serologic IgG crossmatch with antigen negative donor units
  • 3 hospitals reported they perform an antibody screen only and an IgG crossmatch with antigen negative donor units to detect the presence of any new antibodies. A more complete antibody identification is performed every two weeks
  • 2 hospitals reported they test as above however they only repeat an antibody identification every month
  • One group of four hospitals reported that they perform an antibody screen and crossmatch antigen negative donor units (IgG crossmatch). As long as the crossmatch is compatible and there is no change in the strength of the existing antibody these hospitals can follow this protocol. Their policy is to repeat the full antibody investigation only every six months (recently extended from three months after reviewing their historical data).

So, what is the correct practice? Why is there such variation in the approach taken? Is it acceptable to just perform an antibody screen and crossmatch antigen negative units if the patient has a previously identified clinically significant antibody?

 

What do the Standards say about this?
Canadian Standards state that when a clinically significant antibody has been identified, red blood cells that lack the corresponding antigen should be selected for transfusion and be shown to be compatible by serological crossmatch.1,2,3

 

It appears that all of the hospital reported practices comply with the minimum required by Standards, therefore all should be considered acceptable. As resources for hospital transfusion services become scarce, hospitals often need to adjust their practice to conserve these resources. Standards help ensure that decisions made will not jeopardize patient care and will ensure that practice is safe.

 

As far as determining the frequency of performing a repeat antibody investigation to detect the presence of a new antibody in patients who have been recently transfused, many hospitals elect to use antibody screening cells to check if there are any unexpected reactions (any reactivity with antigen negative cell detected or change in strength of reactions) in addition to compatibility testing of antigen negative units.

 

The justification for this being that if a new antibody has developed, the antigen compatible units plus the additional screening cells would provide evidence of a new antibody should unexpected positive reactions be detected. While this practice would be acceptable 4 for most cases, when a patient has developed antibodies against multiple antigens or to a high frequency antigen, screening cells may not provide a good indication if there is another underlying antibody present. Also, to be considered, if the new antibody reacts only with homozygous expressions of the corresponding antigen, the donor units selected for crossmatch may still appear to be compatible. Each hospital should perform a risk assessment to evaluate if the policy they select poses any risk to patient safety prior to implementing it. If an abbreviated investigational approach is adopted, monitoring for possible increased patient risk should take place to ensure the new policy is not causing increased patient harm. For example, monitor transfusion reaction rates.

 

While there is an argument to be made for standardizing processes, it is also important to accept that each hospital must have the flexibility to make decisions based on their own rationale and evaluation. So who is right? All of these practices can be considered acceptable. To repeat or not doesn’t necessarily have to be the question!

 

We encourage hospitals to share any results of their risk assessments by writing an article for the ORBCoN report and/or more formal publications. This may help other sites in considering if they should make a change to their current policy.

 

References:

  1. CSA Z902-15 Canadian Standards Association Standards for Blood and Blood Components December 2015; CSA Group
  2. Canadian Society for Transfusion Medicine Standards for Hospital Transfusion Services; v4 April 2017; CSTM
  3. Institute for Quality Management in Healthcare Medical Laboratory Accreditation Requirements v 7.1 April 2017: IQMH
  4. Fung MK et al Editors. AABB Technical Manual 19th edition; 2017: p378

 

 

 

January 2018

Physician Engagement: Discovering a Common Purpose

By: Stephanie Cope, Administrative Project Coordinator, ORBCoN CE Region

All healthcare professionals, regardless of their role or expertise have the same purpose, ensuring the best possible care for ‘their’ patients. In order to ensure the best possible care is provided, healthcare organizations and physician groups must be able to identify, implement and monitor the available evidence in medicine to ensure best practice(s) are being utilized. One of ORBCoN‘s mandates is to collaborate with transfusion medicine experts and end-users to provide high quality, relevant, evidence-based transfusion medicine educational resources. Achieving buy-in or acceptance for practice changes from the intended end-user groups requires a champion that is well respected, has adopted the new behavior/change and one who has the ability to model and lead their colleagues into current evidence based practices to provide the highest quality of care.

  

ORBCoN regularly evaluates the utilization and accessibility of its educational resources, ensuring they are meeting the educational needs of end-user groups. In 2015-16, it was determined that although the Bloody Easy (10 module) eLearning program was very comprehensive, it took a considerable amount of time to complete, resulting in underutilization by its intended users. Subsequently, this eLearning program was discontinued in order to focus our attention on creating new educational resources that would better meet the end-users’ needs.

  

A first step in increasing physician engagement with transfusion medicine educational resources was to conduct a qualitative analysis. This qualitative analysis would display a better understanding of the effectiveness and relevance of the current formats used to provide transfusion medicine continuing education to ordering physicians/TM Medical Directors. A transfusion medicine educational needs assessment survey was created (LimeSurveyTM) and distributed to all Ontario hospitals through the Laboratory Medical Director and Transfusion Committee Chairperson.

  

Thirty six responses were received. While the number of responses was lower than desired, 22 (61%) of the respondents were from the intended target audience (end-user) and represented all sizes of hospitals.

  

Table 1. What is your motivation when choosing a CME course?

Table 2. How do you prefer to access educational resources?


Table 3. Which of the following are you familiar with? 

As the world of transfusion medicine advances, the importance of providing relevant, current and evidence-based educational resources becomes paramount. Ensuring the potential content is evaluated by the end-user is critical in meeting educational requirements and standardizing transfusion medicine best practices. According to utilization statistics, the Bloody Easy resources are widely used throughout Ontario, Canada and beyond but a gap in user groups is recognized. In future, ORBCoN will strive to promote resources to healthcare practitioners outside of transfusion medicine to extend our education to ordering physicians (of other specialties) to encourage best practice and increase patient safety. A small number of hospitals have made Bloody Easy Lite completion a mandatory requirement for certain healthcare professionals, providing evidence that supports updating the content and the content delivery format. A top priority of ORBCoN is to ensure educational resources are relevant, user friendly and meet the needs of our intended end-users and help hospitals meet the ever increasingly stringent accreditation requirements.

  

ORBCoN would like to thank the following individuals/organizations for providing their support in ORBCoN’s evaluation initiatives over 2015-17: Canadian Blood Services, Choosing Wisely Canada; and Drs: Allison Collins, Elaine Leung, Lani Liebermann, Yulia Lin, Lois Shepherd and Michelle Zeller.

 

  

Bloody Easy on the Road

By: Allison Collins, MD, FRCPC, Clinical Project Coordinator, Transfusion Medicine Physician, ORBCoN

This is an article that does not ask you to do anything, or to learn a new concept, or to embark upon another project, so you can simply relax (or skip it). I am just going to review briefly my experience “on the road”, promoting evidence-based transfusion practices to community hospital physicians over the past four years. It’s been a really fun journey, and I can safely say that this is the best job that I have ever had!

  

The position of ORBCoN Physician Clinical Projects Coordinator was created in November 2013. By then ORBCoN had already made great strides working with hospital blood banks improving inventory management, re-distributing blood products, and auditing transfusion ordering practices, among many other things. Now it was time to give some more educational support to the prescribers of blood, with some friendly reminders about how to order safe and effective transfusions (and obtain informed consent for them). Not being a transfusion medicine specialist, but a general pathologist, I first had to scramble to ensure that my grasp of the subject was even just slightly firmer than that of the people in my audiences, many of whom ask very probing questions. Naturally, the real experts in this field are far too busy to travel any more than they already do, so my position fills in a few of the gaps. Which reminds me to give a big ‘thank you’ to all of the transfusion medicine specialists in Ontario and beyond who have been so generous with their advice and help over the years, and whose slides I so shamelessly borrow and adapt – you know who you are.

  

I have travelled all over the province, sometimes via the Ontario Telemedicine Network, but usually in person. The rough count of presentations so far is about eighty, concentrated mainly in the spring and fall to avoid freezing rain, blizzards, and slippery airport runways. My audiences range from four people to well over a hundred, and include nurses, laboratory technologists, midwives, pharmacists, other hospital staff and, of course, physicians. I suppose I ought to include the audiovisual tech guy at one meeting, who knew nothing about blood but who thought the talk was amusing (potential blood donor?). The knowledge and dedication of the laboratory technologists whom I meet never ceases to amaze me. Perhaps my real role is simply to reinforce the messages that they are already trying to get across in their hospitals, reinforcing the old adage that “no prophet is accepted in his own country”. Although not technically in the job description, I have rearranged meeting room chairs, signed for the delivery of the catering, and served as a source of advice for patients trying to navigate the parking pay machines and exit gates at various hospitals, the latter admittedly with the selfish goal of getting out of the parking lot myself.

  

ORBCoN audits have shown that we need to focus on the indications for and dosing of blood components such as red cells and plasma, which I do. However, I try to tailor the topics to the things the doctors want to hear about (if somebody tells me in advance) or to the things the blood bank staff wants the doctors to know more about (they are pretty good at telling me this in advance). So, we get into platelets, PCCs, warfarin reversal (yes, some people are still using plasma), direct-acting oral anticoagulants, albumin, cryoprecipitate, RHIG, informed consent, transfusion reactions, and on it goes. I have been to a few hospitals multiple times, and asked one anesthesiologist “What on earth is there left for us to discuss next year?”, to which he replied “Just go back to your first talk, we have probably forgotten it by now”. Very reassuring.

  

Finally, a little plug. If you would like to arrange for a presentation to your medical staff you can find me at allison.collins@sw.ca. Our resources at ORBCoN are not unlimited but I will do what I can; the more notice the better.

 

  

  

When should a post-transfusion hemoglobin sample be drawn?

  

The sample can be drawn anytime between 15 minutes and 24 hours post-transfusion1. There are no significant differences in hemoglobin levels over this time frame. Therefore, if a hemoglobin level is part of your patient assessment to determine if another unit of RBCs is required, there is no reason to delay the sample draw past 15 minutes, as excellent hemoglobin correlation exists at the post-transfusion sample draws of 15, 30, 60, and 120 minutes, as well as 24 hours2.

  

References:

  • Wiesen AR, Hospenthal DR, Byrd JC, et al. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann Intern Med 1994;121:278-80.
  • Elizalde JI, Clemente J, Marin JL, et al. Early changes in hemoglobin and hematocrit levels after packed red cell transfusion in patients with acute anemia. Transfusion 1997;37:573-76.   

 

December 2017

Surgery, Blood Transfusion and the Jehovah's Witness Patient

By: John Freedman, MD FRCPC, Professor Emeritus, Medicine, University of Toronto, St Michael's Hospital

For Jehovah’s Witness (JW) the ban on allogeneic blood has been official church doctrine since 1945, and whole blood, red cells, white cells, platelets and plasma are unacceptable to Jehovah’s Witnesses; this is non-negotiable. More recently, this has been modified and currently allows transfusion of ‘minor fractions of blood’ based on individual preference. Bloodless surgery and medicine (Patient Blood Management; PBM) has rapidly evolved over the past few decades. Starting in 1962, Ott and Cooley performed >500 open-heart surgeries on JW patients without use of blood transfusions. PBM continues to improve with new clinical, surgical, and pharmacologic strategies and offers an organized approach to surgery designed to minimize blood loss and to avoid transfusion. These multimodal protocols should be developed by a multidisciplinary team of anesthesiologists, critical care specialists, surgeons, internists, transfusionists, hematologists and bioethicists.

  

Elective surgery needs to be well planned. Both surgeon and anesthetist must meet with the patient to discuss the planned surgical procedure and its associated risks. In an open, non-judgmental fashion they must ascertain exactly what is acceptable to the individual patient. JW patients are generally very well informed and discussion and conclusions should be documented and witnessed. The patient should be encouraged to have a family member or their religious advisor present during this discussion if they wish. Each hospital will have access to a representative from the religion through the local JW hospital liaison committee. Ideally, 4-6 weeks is needed to allow optimization of the patient’s hemoglobin (Hb), if required, and for thorough discussion and planning e.g. are there alternatives to surgery or can the procedure be performed in stages or by a minimal access technique?

  

The preoperative process begins with a thorough history and a detailed physical examination. Preoperative counseling with informed consent is of paramount importance and patients are asked to clearly document which, if any, minor or major fractions of blood they would accept, as well as which bloodless-related preoperative, intraoperative, and postoperative measures they will accept. During the preoperative management, Hb levels should be optimized, and efforts should be made to correctly diagnose and treat any existing anemia. Since preoperative Hb is an important predictor of the need for transfusion one should ensure that these patients start with an adequate Hb. At referral the Hb, ferritin, B12 and folate levels should be checked. The results will determine which patients will benefit from a course of iron or erythropoietin (EPO). If time is short or oral iron therapy is ineffective or not tolerated then intravenous iron may be used. Patients may require both EPO and iron. EPO is expensive and has potential side effects including hypertension and thrombosis which may limit its use in patients over 70 years. It may not be acceptable to all JWs since some preparations contain a small amount of albumin. Also at this planning stage, drugs associated with increased bleeding should be stopped if possible prior to surgery; these include aspirin, NSAIDs and anticoagulants. Blood draws should be minimized and use of pediatric tubes for blood draws may be appropriate, especially if a large number of laboratory tests are being performed.

  

Intraoperative management of the JW patient is complex and requires a high level of technical skill and excellent communication between the surgical and anesthesia teams. Surgical approaches that reduce blood loss, such as handling tissue gently, recognizing potential sources of bleeding and rapidly controlling unexpected hemorrhage, are essential. Patient positioning should maximize access to the surgical field from multiple approaches. Administration of the antifibrinolytic agent, tranexamic acid, can be very useful in reducing blood loss and reducing transfusion in many types of surgery, particularly in cardiac and orthopedic surgery – regimens include intravenous and topical administration. Other techniques may include acute normovolemic hemodilution (ANH) and intraoperative autologous transfusion which may be acceptable to some JWs when performed in a closed system without blood storage; because these interventions are not accepted by all patients, they should be specifically addressed in the advanced directive form.

  

Postoperative measures include tolerance of anemia and minimization of blood draws — lower transfusion thresholds have become acceptable in recent years. Patients should be monitored closely for bleeding and adequate oxygenation. If acute postoperative bleeding is suspected, the surgeon should consider reoperation promptly. Postoperatively, judicious use of intravenous iron and EPO may be considered.

  

Many factors may influence individual patient responses on the advanced directive form. The individual freedom that the JW church provides JW patients in accepting or rejecting minor blood fractions or modern interventions allows for patients to incorporate their own values and the advice of their own support network in the decision-making process. The technical language of an advanced directive may be difficult for some individuals to comprehend, which could lead to inaccurate documentation of a patient’s wishes. Thus, patients should be counseled by physicians and/or trained professionals that are thoroughly familiar with the field of PBM. The counselor must understand both the options presented in the advanced directive and the patient’s beliefs. An attending or resident physician not thoroughly familiar or up to date with PBM techniques may not be able to take such vagaries into account when counseling patients. Treating patients who place restrictions on our medical practice which may ultimately result in morbidity or mortality can raise complex issues of a moral and ethical nature and may be a very stressful experience for all involved, particularly if things do not go well. Nonetheless, we must care for all patients, including JWs, in a professional, non-judgmental and confidential manner. We must work on the presumption that every adult patient has the capacity to make decisions about their care and to decide whether they refuse or agree to any treatment.

 
  

  

Transfusion Medicine Quality Improvement Baseline Survey

By: Troy Thompson, MLT BAHSc (Hons), ORBCoN Regional Manager, Central Region

“The continuous journey has to start somewhere!”

The Ontario Transfusion Quality Improvement Plan (OTQIP) committee conducted a survey in January 2017 to gather baseline data from hospitals on Transfusion Medicine quality improvement (QI) initiatives. As quality improvement is a continuous journey, each hospital may be at various points in the quality improvement spectrum. This article will highlight the QIP survey and the participating hospital’s QI activity.

 

In total, 50 hospital sites participated in the survey, with 31 (62%) sites answering that they have established and implemented transfusion guidelines for blood and blood product utilization. Of the 50 sites, red blood cell (RBC), platelet and plasma guidelines were implemented at 28 (56%), 24 (48%), and 22 (44%) sites respectively while 26 (52%) sites had implemented guidelines for prothrombin complex concentrates (a provision for PCC utilization) and 18 (36%) sites had implemented IVIG guidelines as per the Ministry of Health mandate for IVIG use in Ontario. Transfusion guidelines were approved by a hospital Medical Advisory Committee (MAC) at 29 (94%) sites which may help to support their consistent use. Implementing guidelines is a good place to start when attempting to reduce inappropriate transfusions; 6 (19%) sites answered that the guidelines are followed for “every transfusion order” and 16 (52%) sites answered that guidelines are followed for “most transfusion orders.” The implementation of transfusion order sets (electronic or other) is another strategy that may help in standardizing transfusion practice and 24 (48%) sites answered that they have implemented transfusion order sets. The prospective screening of transfusion orders by a Medical Laboratory Technologist is also an effective way to “curb” inappropriate utilization and 21 (42%) hospitals indicated that they had a prospective screening process in place. This strategy requires much more effort to implement but in combination with consistent medical back-up can be very successful in standardizing transfusion practices. Of those sites that utilize prospective screening, it occurs for “every” or “most transfusion orders” at 10 (48%) sites while 5 (24%) sites screen specific products/components and 6 (29%) sites will screen further if the transfusion order seems questionable.

  

In order to gauge quality improvement success, quality metrics should be measured and 35 (70%) sites indicated that they are measuring quality metrics. Many sites are collecting the percent of transfusions that occur in patients with pre-transfusion hemoglobins less than 80g/L and the percent of transfusions that are ordered as single RBC unit transfusions. These two metrics were also selected by the OTQIP committee and an electronic platform is available for hospitals to enter and track these data. http://etools.transfusionontario.org/. (Please contact ORBCoN if you do not have an account set up). All Ontario hospitals with transfusion services are encouraged to report in this tool because it provides hospitals with individual progress reports to share with their internal quality and transfusion committees and ORBCoN can generate combined data reports to monitor progress at a provincial level.

  

Quality improvement initiatives in Transfusion Medicine continue to increase and the reduction of unnecessary tests/procedures such as transfusion is a key component for patient safety as highlighted in the Choosing Wisely Canada campaign. Momentum in Transfusion Medicine QI is gaining and it is important to measure your progress as you work towards your goals. No matter what stage you are at in the QI journey, the journey starts with you, so check out the Ontario Transfusion Quality Improvement Plan at www.transfusionontario.org and make your QI goals today!

  

“Practice the philosophy of continued improvement; get a little bit better every single day.” Author unknown

 

  

   

Question submitted in response to June 2017 Newsletter article titled "How do we interpret the 60 minute rule"  Authored and Responded By: Yulia Lin, MD, FRCPC, Transfusion Medicine Specialist, Sunnybrook Health Sciences Centre

  

1. The study was performed on RBCs, but the standard is for all blood components. Is there no need to do studies on other blood components before generalizing the standard to include all components (i.e. plasma)?

  

The study was specifically performed for RBCs. Practically speaking and in my personal opinion, I don’t see much of an issue with the 60 minute rule being extended because:

  • Plasma is thawed at 37°C and I think there is minimal decay in the factors whether stays out of lab for 30 minutes vs. 60 minutes. Technically, it just has to be cooler than when it left the lab which will be the case.
  • Platelets are kept at room temperature so again 30 minutes vs 60 minutes shouldn’t really make a difference. The lack of agitation for 30 vs 60 minutes is not an issue considering that they may sit up to 24 hours during transport.
  • Cryoprecipitate also kept at room temperature after thawing again so 30 vs 60 minutes will not be an issue.

  

2. You mentioned a little section about blood products can also be returned to useable inventory provided they have not been outside of a controlled environment for more than the time recommended by the manufacturer. The standard (14.6.2) says the product must be maintained within the “parameters” described in the product monograph. I’m thinking parameters probably also includes temperature as well. As in, if a vial of WinRho was issued out of the lab and came back greater than 8 degrees, it cannot be returned to useable inventory. Your thoughts?

 

Interesting that you comment on the blood products – that specific section was actually added in conjunction with ORBCON. The parameters would also include temperature. For certain products, we have sought additional information from the manufacturers (outside of the product monograph) on product stability so that has helped us extend some products even longer.

 

November 2017

Transfusing Wisely at Scarborough and Rouge Hospital

By: Tina Irwin, Charge Technologist, Transfusion Medicine, Scarborough and Rouge Hospital

Choosing Wisely initiatives are necessary to improve utilization of blood products, to minimize the patient risks associated with transfusion and decrease the costs to hospitals and ultimately to healthcare by eliminating unnecessary testing and usage of this valuable commodity.

  

The first step to implementing Choosing Wisely initiatives in Transfusion Medicine is to establish a baseline audit to determine the strengths and weaknesses of current practices. With the support of the Transfusion Committee and the ONTraC nurse at Scarborough and Rouge Hospital, formerly The Scarborough Hospital (General / Birchmount), we established the criteria for our baseline audit. The patient focus group did not include Oncology, Hemodialysis or actively bleeding patients. Transfusion data from 50 eligible patients at each Campus, (Birchmount / General) was analyzed and compared.

  

Five main indicators were measured:

  1. Patients with a pre-transfusion hemoglobin <80 g/L.
  2. Single unit transfusions followed by hemoglobin (CBC) and patient reassessment.
  3. Patients with a post-transfusion hemoglobin value >100 g/L.
  4. Inappropriate transfusions based on our current guidelines.
  5. Patients without a post-transfusion hemoglobin value.

From the baseline audit data conducted in April 2016, it was evident that a plan must be initiated to improve our blood utilization. Between July 2016 and September 2016 we implemented several improvement strategies suggested by The Ontario Transfusion Quality Improvement Plan (OTQIP), ORBCoN, ONTraC, Bloody Easy and Choosing Wisely Canada.

  1. Standardized transfusion guidelines were established. The guidelines were delivered in laminated poster form to every department, nursing station and physician lounge across both hospital sites (General / Birchmount).
  2. Revision of our current blood transfusion order set to include a mandatory CBC or hemoglobin after each transfused unit of red blood cells.
  3. Physician education took place in the form of Medical Rounds from Dr. Allison Collins and Dr. Jackie Ostro. Letters from our Chief of Staff, Laboratory Medical Director and Transfusion Committee Chair were delivered notifying all physicians of the transfusion guidelines update, revised order set and our baseline audit results.
  4. Nursing education consisted of visiting each nursing unit and attending staff huddles to discuss transfusion requirements and guidelines with focus on post-transfusion hemoglobin values.
  5. Prospective screening of transfusion requests required training for Medical Laboratory Technologists and was implemented with extra support available upon request.
  6. A post implementation audit was performed by Tina Irwin et al. in November 2016 to determine the effectiveness of the implemented strategies. Additional audits were performed every 3-5 months thereafter, to measure sustainability (See results below).

Transfusion Audit April 2016-August 2017 Scarborough and Rouge Hospital (General / Birchmount Campus)

In addition to transfusion restrictions, it was determined by an audit that 40-50% of the group and screen tests in the Oncology department were unnecessary as the patients did not require a blood transfusion on that visit. We implemented a “BBHOLD” order in our LIS where a sample is collected but not tested unless a transfusion is indicated. As a result there has been a reduction in both group and screen testing and antibody investigations with an approximate savings of >$50,000/year in reagents and supplies.

  

The implemented Choosing Wisely initiatives, with interprofessional communication and continuous monitoring, have proven to be successful and sustainable for improving blood utilization at the Scarborough and Rouge Hospital (General / Birchmount).

  

 

Doing Away with the SickleDex: UHN Red Cell Disorders Program Policy Change

By: Christine M. Cserti-Gazdewich, MD, FRCPC, FASCP, Transfusion Medicine Specialist & Consultant Hematologist, University Health Network

Red cell transfusion (RBC) strategies in sickle cell disease (SCD) range from simple transfusions to therapeutic exchanges (TREx), aiming to improve tissue oxygenation as the quantity and/or quality of hemoglobin (Hb) increases. In TREx, sickle hemoglobin (HbS) is taken from its baseline levels to targets at or below those in sickle cell trait (SCT) (ie- HbS ≤30%). The assurance of trading out HbS (or the power to verify achieved vs expected HbS%) rests on assumptions that RBC are HbS-free. However, the odds of a SCT+ RBC increase by matching practices in SCD. Many transfusion services therefore test for SCT, so as to exclude HbS+ units allocated to SCD patients. If half of surveyed jurisdictions do this, which half is right?

 

In our program, ~3500 RBC units (or 1 in 10 units) are transfused annually to SCD patients. In our audit (12/5/2009 – 21/01/2017, >7.5 years), 26003 RBC were SCT-screened, at $10/test. Only 2-3 RBC/1000 were found to be SCT+. In the most recent fiscal year, SCT testing costed $44,300. For the 13 SCT+ units found, the number-needed-to-test was 341. Said another way, $3408 was spent to interdict any SCT+ unit. This excluded costs related to new workload or delays in care. The chance of SCT+ RBC incorporation in TREx was therefore deemed low, with stakeholders agreeing that such an event would also be inconsequential (in calculations or clinical outcomes).

 

We concluded that the cost of RBC SCT testing, against the benefits gained (or risks averted), could not justify continuation. Analogously, we accept crossmatch compatibility as a surrogate for antigen-negativity for those targets which are infrequent in their occurrence, expensive to select, and usually harmless on transfusion otherwise. In the spirit of informed decision-making, we have abandoned SCT testing of RBC.

  

References

  • Bello NA, Hyacinth HI, Roetker NS, et al. Sickle cell trait is not associated with an increased risk of heart failure or abnormalities of cardiac structure and function. Blood. 2017; 129(6):799-801.
  • Lanzkron S, Naik RP. Negative studies shape the state of sickle trait. Blood. 2017; 129(6): 661-662.
  • Liem RI, Chan C, Vu TT, et al. Association among sickle cell trait, fitness, and cardiovascular risk factors in CARDIA. Blood. 2017; 129(6):723-728.
  • Kelly S, Quirolo K, Marsh A, Neumayr L, Garcia A, Custer B. Erythrocytapheresis for chronic transfusion therapy in sickle cell disease: survey of current practices and review of the literature. Transfusion. 2016; 56(11):2877-2888.
  • Ould Amar AK. Red blood cells from donors with sickle cell trait: a safety issue for transfusion? Transfus Med. 2006;16(4): 248-253.
  • Quirolo K. How do I transfuse patients with sickle cell disease? Transfusion. 2010; 50(9): 1881-1886.
  • Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014; 312(10): 1033-1048.
  • Yazer MH, Lozano M, Crighton G, et al. Transfusion service management of sickle-cell disease patients. Vox Sang. 2016; 110(3): 288-294.

 

October 2017

Testing the Triage Team –

The New Brunswick Experience

By: Anne Marie Robinson, Transfusion Medicine Supervisor, South East RHA, Horizons New Brunswick

February 16-19, 2016, the Provincial Emergency Blood Management Committee (PEBMC), Canadian Blood Services (CBS) and the Regional Health Authorities in New Brunswick participated in a simulation exercise to test the process in a Red Phase blood shortage. Previous exercises, both announced and unannounced, were focused on laboratory preparedness. The 2016 exercise was developed to highlight the importance of the triage team and the need for the participation of physicians, nurses and other health care professionals in managing a true shortage.

  

While there was advance notice, the actual date of the exercise was unknown to the Regional Health Authorities (RHAs). The Transfusion Medicine labs were notified by Fax and telephone call and then 2 sealed envelopes containing 10 scenarios were delivered with the CBS order that morning. We were provided with a Red phase inventory of red blood cells (RBCs) which were available to be allocated to our 10 patients.

  

The cases presented ranged from request for RBCs for chronically anaemic patient to motor vehicle crash and ruptured aortic aneurysm.

  

The triage team convened and reviewed 5 cases each day, using the guidelines in the National Emergency Blood Management Committee (NEBMC) Emergency framework for rationing of blood for massively bleeding patients during a red phase of a blood shortage – Synopsis for Triage Team to assist with allocation of red cells. The cases were reviewed one at a time and as a decision was reached, the inventory was reduced prior to review of the next case.

  

This exercise was invaluable in helping the members of our newly formed Triage team understand their roles and responsibilities.

  

  1. It brought home the reality that in a red phase shortage, there would be patients who would be denied transfusion and that those patients may not survive.
  2. It was very helpful in helping all of the members of the triage team in clarifying their roles. (Example Social workers, spiritual care, palliative care)
  3. It highlighted the physicians who were missing from our team (surgeons), liaison with ambulance services.
  4. The RHAs need to develop consistent messaging for patients affected by the shortage.
  5. Even though it was a paper exercise, it was a very emotional experience and reinforced the reality that in a severe blood shortage, we would be unable to treat our patients in the manner to which we are accustomed.
  6. Documentation of decision making is of crucial importance. A designated scribe is essential.

Our thanks to Gail Samaan, Health Care Consultant NB Department of Health and Dorothy Harris, Canadian Blood Services Hospital Liaison Specialist for development of the excellent scenarios.

  

 

Use of Irradiated Blood Components

By: Allison Collins, MD, FRCPC, Clinical Project Coordinator, Transfusion Medicine Physician, ORBCoN

Irradiated cellular blood components (red blood cells [RBCs], platelets, and granulocytes) are used for transfusion recipients at risk of transfusion-associated graft versus host disease (TA-GvHD). Immunocompetent T lymphocytes in the transfused component can attack the immune system of immunocompromised recipients, causing TA-GvHD, which is almost invariably fatal. Immunocompetent recipients can also develop TA-GvHD if transfused with HLA-similar (haploidentical or matched) components, in which case the donor blood is not recognised as foreign by the recipient, but the recipient tissues are recognised as foreign by viable donor T lymphocytes. Irradiated components are provided by Canadian Blood Services (CBS) for hospitals which do not have an on-site irradiator. Although leukoreduction appears to reduce the risk of TA-GvHD, it is not considered sufficient.

 

Bloody Easy 4, and Chapter 15 of the on-line version of the CBS Clinical Guide to Transfusion both discuss this topic, and provide lists of the type of recipients who must receive irradiated blood components1, 2. The National Advisory Committee on Blood and Blood Products (NAC) will also be publishing recommendations on the use of irradiated blood components. The draft document is available on the internet3, but watch the official NAC website for the final recommendations, due to be posted in the fall of 20174. Patients requiring irradiated components should wear an ID bracelet or carry a wallet card stating this fact.

 

Irradiated RBC components show more hemolysis than non-irradiated red cells, and contain higher concentrations of potassium. CBS and many hospitals have adopted the Council of Europe Guidelines for the use of irradiated components, which state that red cells may be irradiated up to 28 days after collection. They must then be transfused as soon as possible, but no later than 14 days after irradiation and, in any case, no later than 28 days after collection. The guideline is more strict for neonates5. Because of the lower quality of the component, irradiated RBCs should not be given to patients who do not require them.

 

What do you do if a transfusion is urgent, there is no on-site irradiator, and the delay for delivery of irradiated components is unacceptable to the ordering physician? A recent systematic review of TA-GvHD found that the storage duration of the implicated component was less than or equal to 10 days in 94% of 348 cases6. Other studies have shown that the oldest component implicated in TA-GvHD was less than or equal to 14 days old. Therefore, the use of non-irradiated components greater than 14 days old may be an alternative when irradiated blood is not available and the need for transfusion is urgent.

 

Situations Requiring Irradiated Blood Components1,2,3

  • intrauterine transfusion (IUT)
  • neonatal top-up transfusion or exchange transfusion if previous IUT
  • neonatal exchange transfusion unless transfusion would be delayed
  • neonatal top-up transfusion in neonate less than 4 months of age or less than 1200g
  • confirmed 22q11.2 deletion (Di George syndrome)
  • congenital cardiac abnormalities until 22q11.2 deletion excluded
  • congenital T-cell immunodeficiency
  • use of HLA-matched platelets
  • directed donation from first- or second-degree relatives
  • Hodgkin lymphoma
  • allogeneic and autologous hematopoietic stem cell or bone marrow recipients (see references for details)
  • current or previous therapy with purine analogues (fludarabine, cladribine, deoxycoformicin)
  • current or previous therapy with purine antagonists (bendamustine, clofarabine)
  • current or previous therapy with the potent T-cell inhibitor alemtuzumab (anti-CD52)
  • aplastic anemia treated with anti-thymocyte globulin
  • granulocyte transfusion (granulocyte concentrates are not provided by CBS but are provided by Héma-Québec)

References

  1. Callum JL et al. Bloody Easy 4: Blood Transfusions, Blood Alternatives and Transfusion Reactions, pages 70-71. Ontario Regional Blood Coordinating Network, 2016. Available at www.transfusionontario.org
  2. Clinical Guide to Transfusion, Chapter 15. Canadian Blood Services, 2017. Available at www.blood.ca
  3. National Advisory Committee on Blood and Blood Products, draft Recommendations for use of Irradiated Blood Components in Canada. Available at http://www.canadianneonatalnetwork.org/Portal/LinkClick.aspx?fileticket=itlU1wecNPw%3D&tabid=39
  4. National Advisory Committee on Blood and Blood Products www.nacblood.ca
  5. Guide to the preparation, use and quality assurance of blood components. Council of Europe, 2017, pages 188 and 274. Available at https://www.edqm.eu/en/blood-transfusion-guides-1608.html
  6. Kopolovic I et al. A systematic review of transfusion-associated graft-versus-host disease. Blood 2015;126(3):406. Available at www.bloodjournal.org

 

September 2017

Provincial Redistribution Update:

Change is afoot!

By: Tracy Cameron, Regional Project Coordinator, ORBCoN

With the growing anticipation of Canadian Blood Services (CBS) implementation of new insulated shipping containers (ICSs), Ontario hospitals are getting ready for a big change in how they ship components and products between sites as well as transport to the emergency rooms and operating suites.

  

CBS announced in early 2015 that they would be implementing new ICSs that would include a single packing configuration suitable for all seasons, allowing a greater number of products to be shipped to hospitals and eliminate the use of dry ice as a refrigerant for frozen products. But with the new ISCs comes a restriction for hospitals not to use them for redistribution or transfer of product, since the preconditioning of the plates used to maintain the temperature within the shipping container is a two stage process and requires specialized equipment. Hospitals are being asked to continue to use the J82 shipping containers to ship red blood cells (RBCs) and refrigerated blood products, as well as the E38 shipping containers to ship platelets and room temperature blood products for the purpose of redistribution, transport to other patient care areas, and for products transferred with a patient to external facilities. These containers will continue to be supplied by CBS and hospitals will be able to order them similar to placing an order for products. However the validation of these boxes will not be supported by CBS any longer.

  

What can hospitals expect for the redistribution program and transferring components and products with a patient?

  

ORBCoN has partnered with two hospitals to validate the J82 and E38 shipping containers at different temperature points that mimic possible ambient temperature conditions during transportation. The containers are being challenged at extreme warm temperatures (35 to 40°C), room temperature (19 to 25°C), mild temperatures (1 to 6°C) and extreme cold temperatures (-30 to -35°C). The data collected will determine how long the shipping containers can maintain the required acceptable temperatures for shipping components and products with a minimal payload and a maximum payload.

  

During the validation, questions arose regarding the packing configuration of the J82 containers and how hospitals currently precondition the ice packs for the container. In 2016 we asked hospitals what temperature freezer they had available and 59% of the hospitals responded saying they currently use a freezer with temperatures as cold as -40°C. Most hospitals were preconditioning freezer packs between -25 and -40°C. In a more recent survey we asked hospitals if they had access to a freezer with temperatures between -25 and -40°C and if they had room in their freezer for ice packs for preconditioning. Table 1 shows the results from the survey. The data justified keeping the packing configuration protocol to just preconditioning ice packs between -25 and -40°C and not expand the validation to include preconditioning ice packs in warmer freezers (-18 to -22°C). Hospitals wishing to participate in the redistribution program must meet the requirements of freezer temperature and size capacity to precondition ice packs.

 

The original CBS packing configuration for the J82 container required 2 ice packs to be preconditioned between -11 and -14°C for the products to maintain the required acceptable temperature for up to 24 hours. This packing configuration will be changing slightly to using only one freezer pack preconditioned between -25 and -40°C for at least 6 hours prior to use. This, along with a few other minor changes to the packing configuration, will be provided in an updated Provincial Redistribution Toolkit that is currently being revised by a provincial working group.

 

What can you expect to find in this toolkit?

 

The working group is revising operating procedure templates for the redistribution of fresh components as well as the redistribution of blood products using the J82 and E38 shipping containers. The operating procedure for the Golden Hour containers will also be updated and included. The toolkit will include a standardized inter-hospital transfer form that is to be used when redistributing any products as well as a new memorandum of understanding (MOU) for hospitals that are participating in the redistribution program. Revisions are also underway for the operating procedure template for transferring blood components and products with a patient to an external facility. A training package is being developed to help lab staff become familiar and competent with the revised redistribution process. The target date for the release of the toolkit is late October early November 2017.

  

Redistribution of frozen products may not be an option for some hospitals that do not have access to dry ice. CBS will phase out the use of dry ice to ship frozen products, and hospitals will have to use their own supply if they want to continue to redistribute frozen products. The working group recognizes this issue and ORBCoN and CBS have been notifying hospitals during site visits.

  

As always if you have any questions or concerns please contact us at info@transfusionontario.org

  

 

Blood Products and Critical Care

Transport in Ontario

By: Russell D. MacDonald, MD, MPH, FCFP, FRCPC, Ornge Transport Medicine

Ornge is the air medical and land critical care transport agency in the Province of Ontario. Using its fixed wing aircraft, helicopters, and land-based critical care transport vehicles, Ornge carries out approximately 20,000 patient transports each year, making it Canada’s largest critical care transport service. Advanced and critical care paramedics are highly skilled providers and function under a ‘delegated acts model’, under the auspices of a dedicated transport medicine physician. The paramedic scope makes it possible for them to provide care comparable to that in an intensive care unit.

 

Ornge is a key stakeholder in Ontario’s regionalized health care system, enabling patients to access specialized or tertiary care services in a timely manner. Most patient transports take place between two hospitals, referred to as ‘inter-facility’. Ornge’s helicopters also respond to ‘scene calls’, where the helicopter lands at the roadside, in a farmer’s field, or some remote location, to transport patients with acute life-threatening injury or illness directly from the scene to a hospital. For many, particularly in northern Ontario, Ornge is the only access to definitive care due to distance or lack of road access in remote communities.

 

In 2016, Ornge delivered 570 units of blood product to 335 patients. Common indications include hemorrhagic shock in trauma, post-partum hemorrhage, gastrointestinal bleeding, and hematologic malignancies. Ornge aircraft and crews do not carry blood products. Ornge acquires blood products from the sending facility, and administers them in partnership with sending facility staff. Ornge adopted Sunnybrook Health Sciences Centre’s practices for blood product administration, and modified them to meet the transport environment. All blood product administration requires an order from the Ornge transport medicine physician. The lack of blood products in many locations Ornge services poses a unique challenge to meet patient care needs. The longest transports occur in Northern Ontario, and the north accounts for a disproportionate number of calls. Many northern hospitals have limited or no blood product, and nursing stations do not have any. Each week, there are one or two patients that Ornge transports who meet indications for time-sensitive blood product administration, but no blood product is available.

 

Ornge carried out an environmental scan of Canadian critical care transport agencies to identify how they access blood products. In four provinces, transport agencies partnered with Canadian Blood Services to make blood product available at the transport agency’s bases, or accessible from a central blood bank in a timely manner.

 

Ornge’s Medical Director met with the Ontario Regional Blood Coordinating Network in June to discuss a partnership to develop an information exchange system to enhance traceability of all blood products administered by Ornge’s paramedics, and to develop ways to make blood products available at Ornge’s bases in northern Ontario. The partnership is in its infancy, with goals of meeting patient care needs and enhancing accountability for blood product used in delivery of care. For more information about Ornge or this initiative, please contact Troy Thompson (troy.thompson@sunnybrook.ca) or Dr. Russell MacDonald (rmacdonald@ornge.ca).

  

 

June 2017 Newsletter

How do we interpret the “60 minute” rule?

By: Yulia Lin, MD, FRCPC, Transfusion Medicine Specialist, Sunnybrook Health Sciences Centre

Six years ago, I wrote an article for the ORBCON newsletter entitled “How do we interpret the 30 minute rule?” The article referred to the CSA Z902-10 standard 10.10.5 (c) that states that “a blood component that has been returned to the transfusion service shall not be re-released unless a suitable temperature monitoring system indicates that the blood or the blood component has not reached an unacceptable temperature since being released or, in the absence of a temperature-monitoring system, that the blood component has not been outside of a controlled environment for more than 30 minutes (measured by occurrence, not cumulatively).” At that point, we reported on a survey of 110 Ontario hospitals (73% response rate) which showed variable interpretations of the CSA clause: 45% discarded RBC units based on time (30 minutes) alone; 13% discarded RBC units based on temperature (10oC) alone; 25% required that both time and temperature criteria were met; 13% discarded RBC units regardless of temperature or time spent outside of the blood bank. In 2009, 33 Ontario hospitals reported that they had discarded 457 RBC units for not meeting this standard.

 

I am delighted to report on the changes that have happened over the past 6 years! As a result of the impact of this standard, Dr. Sandra Ramirez-Arcos from Canadian Blood Services led multiple studies providing evidence that RBC units that have been outside of controlled temperatures for repeated exposures of 60 minutes had the same quality and were as safe from a bacterial contamination perspective as RBC units that had been outside of controlled temperatures for repeated exposures of 30 minutes1,2. The average temperature that was reached at 60 minutes was 14.2oC ± 0.2oC. Researchers, Marie Joëlle de Grandmont and Dr. Louis Thibault from Héma-Québec conducted similar studies with concordant results3. Based on these Canadian research findings, the CSA Z902-15 standards were updated from 30 minutes to 60 minutes.

 

So how do we apply this into our blood bank inventory practice? The CSA Z902-15 standard in fact does not specify that the temperature needs to be taken when a RBC unit is returned to the blood bank. Many blood banks have interpreted this clause as: if the RBC unit is returned to the blood bank from a clinical area within 60 minutes, it can be returned to inventory. A few institutions continue to measure the temperature of RBC units on return and some are mandated to if they are AABB accredited institutions. At our centre, we have instituted the following: For RBC units returned from a clinical area to the blood bank within 60 minutes, the temperature should not exceed 14oC. This reflects the data that was conducted in Canada by Ramirez-Arcos and de Grandmont1-3. The Canadian AABB-accredited institutions have also been granted a variance from the AABB standard 5.26 by the AABB Standards Program Committee.

 

Of course, the best case scenario is to avoid having RBC units returned from the ward. So as I finished off my article 6 years ago, I leave you with the same advice: we need to prevent returns of issued RBC units by making sure the patient is ready for and aware of the transfusion with the correct transfusion order, a properly completed consent and a patent intravenous line before the blood arrives on the ward. Happy SOP changing!

 

Editor’s note
Blood products such as albumin, IVIG, RHIG etc. may also be returned into usable inventory, provided that the product has not been outside of a controlled environment for more than the time recommended by the manufacturer.

 

References:

  1. Ramirez-Arcos S, Perkins H, Kou Y, Mastronardi C, Kumaran D, Taha M, Yi QL, McLaughlin N, Kahwash E, Lin Y, Acker J. Bacterial growth in red blood cell units exposed to uncontrolled temperatures: challenging the 30-minute rule. Vox Sang 2013;105: 100-7.
  2. Ramirez-Arcos S, Kou Y, Ducas E, Thibault L. Changing the 30-min Rule in Canada: The Effect of Room Temperature on Bacterial Growth in Red Blood Cells. Transfus Med Hemother 2016;43: 396-9.
  3. de Grandmont MJ, Ducas E, Girard M, Methot M, Brien M, Thibault L. Quality and safety of red blood cells stored in two additive solutions subjected to multiple room temperature exposures. Vox Sang 2014;107: 239-46.

 

Quality Indicators in the Ontario Transfusion Quality Improvement Plan: How Are You Doing?

By: Allison Collins MD FRCPC, ORBCoN Physician Clinical Coordinator

The Ontario Transfusion Quality Improvement Plan (“the OTQIP”) was introduced in April, 2016. The toolkit which accompanies the OTQIP includes a guidance document, a quality improvement plan narrative, recommendations for the use of blood components in adult inpatients, template order sets for adult inpatients, a template standard operating procedure for red cell order screening by blood bank technologists, an educational presentation about red cell order screening (including case studies), and a tracker tool to track audit results over time. The two quality indicators in the OTQIP are 1) percentage of red cell orders with a pre-transfusion hemoglobin less than 80 g/L and 2) the percentage of red cell transfusions which are single unit (one unit at a time) transfusions. The target goal for each of these indicators is 80%, based on the results of the 2013 ORBCoN Red Cell audit. For more details, including suggestions for how to do a simple audit, go to the ORBCoN website www.transfusionontario.org and click on the Quality Improvement tab.

 

As I travel around the province doing educational presentations about blood transfusion, I am asking hospitals if they are willing to share the data they have collected for the two indicators above. This a bit unscientific because hospitals may be auditing slightly different patient populations, but it may be helpful in these early days of implementing the OTQIP to show hospitals how they are doing compared to others. All data is presented without naming hospitals. The information has been of great interest to the audiences, some of whom may not be very familiar with the OTQIP or their own data. Here is what I have collected so far:
            

 

Notes to the graphs: The 2013 data in both graphs are from the 2013 ORBCoN Red Cell audit. Two hospitals are shown more than once in each graph because they have done multiple audits over time. Hospitals have data on one or the other indicator, or both. All are community hospitals except for two.

 

The graphs appear to indicate that restrictive transfusion thresholds are becoming more widely used, while the use of single unit transfusions is quite variable. The adoption of a single unit policy has actually been shown to reduce red cell utilisation more than adherence to restrictive pre-transfusion hemoglobin thresholds1.

 

All hospitals are encouraged to consider adapting the OTQIP to their own use, and/or to submit indicator data to ORBCoN using the tracker tool in the OTQIP toolkit. Then, we’ll have more robust data to show you and will be able to track overall provincial performance over time. The OTQIP could also be used to improve performance in the transfusion of other blood components, such as plasma.

 

References:

  1. Yang WW et al. Single-unit transfusions and hemoglobin trigger: relative impact on red cell utilization. Transfusion 2017;57:1163

 

What’s New from ORBCoN

ORBCoN strives to improve patient safety and standardize best practices in Transfusion Medicine by continuing to support the availability of educational resources to our Ontario stakeholders. The following new or revised resources are now available through transfusionontario.org.

An electronic tool has been developed in order to capture RBC quality improvement (QI) metrics. The QI metrics include the percentage of pre-transfusion hemoglobin <80 g/L and the percentage of single unit transfusions. This tool is available in the ORBCoN e-tools application.

ORBCoN also maintains awareness of accreditation requirements for Transfusion Medicine and monitors any potential needs that may arise and will continue to provide resources for Ontario hospitals to help meet these accreditation requirements. Bloody Easy Tech Assessments 2016 questions are now available through e-tools on transfusionontario.org.

 

New to e-tools? 
Contact your regional office to set up a site administrator.

 

Do you have a Transfusion Medicine quality improvement initiative or utilization improvement activity from your hospital that you would like featured in the ORBCoN Report? We want to hear from you, contact us at transfusionontario.org or contact your regional office.

 

May 2017 Newsletter

Educational Videoconference Symposium: Another Great Success 

By: Tracy Cameron, ORBCoN Project Coordinator, NE Ontario  
Since 2007, a partnership has existed between Canadian Blood Services (CBS) and the Ontario Regional Blood Coordinating Network (ORBCoN) to plan, co-chair, provide funding for, and execute annual transfusion medicine conferences. Each year a videoconference event is coordinated by ORBCoN and CBS, and is hosted at a community hospital. Hosting at a community hospital serves two purposes – the first is to provide the speakers with an on-site audience which helps in the delivery of the presentations; the second is to meet the objective of the event, which is to provide basic transfusion medicine education for non-transfusion specialists in community hospitals. The host site is also involved with the planning and often provides a local speaker whenever possible. This year we had two co-hosting sites, Health Sciences North and University Health Network – Toronto General. Topics are usually picked based on feedback from our community hospital partners on issues they often encounter and look for help with from larger centres, as well as suggested topics from previous year’s attendees.

This year’s conference focused on managing patients with GI bleeding and liver disease, with the objective of identifying key factors that determine the need for transfusion in community hospital emergency rooms when dealing with a GI bleed. There were four dynamic speakers that highlighted some tools to help assess the severity of the GI bleed, provided best practices for treating bleeding in patients with advanced liver disease, compared the available options for anticoagulant reversal in the GI bleed setting, and discussed strategies for improving red blood cell utilization.
 

How do we measure the success of this event?
One hundred and seven healthcare facilities joined the conference either by videoconferencing or webcasting through the Ontario Telemedicine Network. Twenty-three of those 107 sites were from out of province making this event a national one. There were also 9 Canadian Blood Services sites that attended, along with two pharmaceutical companies and 1 post-secondary institute. We believe that our high attendance rate and seeing our event uptake expand across the country is a good indication that this event is providing the necessary information for those who attend.

Who attended?
There were 1038 in attendance between the morning session and the afternoon session. The afternoon session was a repeat of the morning session and is designed to allow for flexibility in attendance due to conflicting responsibilities during working hours.

The figure below illustrates who was in attendance for this year’s event.

How did attendees evaluate the event?
96% of the attendees said they would recommend this educational event to their colleagues, and 77% indicated that after attending this event they would somewhat modify their practice behavior. Some of the comments received from attendees have included;

 

“This is a great learning experience, with wonderful speakers. I was able to come away with a better overall picture as to the care and decisions towards a patient.” 
“Very good topics, I believed they covered everything and it was really interesting”
“I liked that you had the two sessions, very helpful for staff that were on the job”


If you missed the presentations, you can access them via archive through the ORBCoN website on our webcasting centre and they will be available for one year. The PowerPoint presentations are also available on our “What’s New” on our main page and also in our presentation library under the ORBCoN Resources page.
 
If you have any suggestions for future topics that you would like to see covered by this event please send them to info@transfusionontario.org

 

Informed Consent for Transfusion

By: Dr. Allison Collins 
Transfusion of blood components and blood products may be life-saving, but is not without risk. As with other medical treatments, informed consent is required for blood transfusion. Justice Horace Krever, in his report on the blood system in Canada, defined the requirements for informed consent as follows:

  1. that the treating physician obtain informed consent from the patient, barring incompetency or an emergency procedure,
  2. that risks, benefits, and alternatives be presented in language the patient will understand and in a manner that permits questions, repetitions, and sufficient time for assimilation,
  3. that the discussion take place well in advance of the therapy to enable the patient to employ alternatives to allogeneic blood transfusion and,
  4. that the treating physician document in the patient’s chart that the risks, benefits, and alternatives to blood transfusion have been discussed (1). According to the Canadian Standards Association, transfusion services must have policies in place to ensure that informed consent is obtained before transfusion (2).

The Canadian Society for Transfusion Medicine has published recommendations to facilitate the process of informed consent to transfusion (3). These include providing prescribing physicians with up to date information about the risks, benefits, and alternatives to transfusion, providing orientation and ongoing education for physicians and other health care providers involved in the transfusion process, and auditing compliance with the informed consent process. Compliance with the informed consent process of less than 90% should prompt action to improve it.
 
The Canadian Medical Protective Association (CMPA) states that the obligation to obtain informed consent rests with the physician who orders the treatment (4). It also recommends that, even when patients waive aside all explanations or seem to be prepared to undergo a procedure or treatment without discussion, it should be explained that the risks should still be discussed. Print material, videos, and other handouts all support the consent discussion but do not replace it (5).
 
Nurses are important members of the health care team, but are not responsible for obtaining informed consent for transfusion. They will, however, explain the transfusion process to the patient and determine if informed consent has been obtained. The College of Nurses of Ontario Practice Guideline states that a nurse should not provide a treatment if there is any doubt about whether the patient understands and is capable of consenting to the treatment, even if there is an order (6).
 
The Ontario Regional Blood Coordinating Network (ORBCoN) provides lanyard cards summarizing the elements of informed consent and the risks of transfusion. Additional information is available in the ORBCoN publication “Bloody Easy 4”. Both can be ordered from ORBCoN if the transfusion medicine laboratory does not already have them on site (7).

References

  1. Krever, H. Commission of Inquiry in the Blood System in Canada, final report, Appendix H. Government of Canada publications. 1997
  2. CSA Standard Z902-15. Blood and Blood Components, clause 11.2.1. Canadian Standards Association 2015.
  3. Informed Consent – Position Paper. Canadian Society for Blood Transfusion 2012.
  4. Evans KG. Consent: A guide for Canadian physicians, fourth edition. Canadian Medical Protective Association May 2006, updated June 2016. Available at www.cmpa-acpm.ca
  5. Canadian Medical Protective Association Risk Fact Sheet Informed Consent 2016.
  6. Consent Practice Guideline. College of Nurses of Ontario 2017.
  7. Ontario Regional Blood Coordinating Network www.transfusionontario.org

 

 

 

 

April 2017 Newsletter


Transfusion Quality Improvement:
One Hospital’s Story 

By: Krista Walters, Charge Technologist, Mary Green, Laboratory Manager Niagara Health System (NHS) and Denise Evanovitch, ORBCoN Regional Manager, SW Ontario  

Niagara Health System (NHS) consists of five community hospitals: Douglas Memorial in Fort Erie, Greater Niagara General in Niagara Falls, Port Colborne, St. Catharines and Welland. NHS also provides Transfusion services to Hotel Dieu Shaver Rehabilitation Hospital.

  

Like other hospital transfusion services, NHS is continually looking to improve quality and safety in many areas, including transfusion. We have looked to ORBCoN and the Ontario Transfusion Quality Improvement Plan (OTQIP) for guidance, and actually, NHS was one of the hospitals that piloted the e-tool designed to collect and analyze the relevant quality improvement data.

 

Our successes to date include:

  1. An audit of all blood components to establish a baseline of appropriateness.
  2. Utilization guidelines for blood components and accompanying order set which was approved and deemed mandatory for use on February 9, 2017 by the Order Set Committee. This committee acts on behalf of the MAC on specific issues. The Chair of Order Set Committee, a physician, supports the use of order sets and regular auditing to gauge compliance. Follow up and discussions will occur with physicians and departments when components orders fall outside of the hospital’s guidelines.
  3. The % single unit RBC transfusions (ordered and transfused) rate is now a Corporate Quality and LHIN wide Indicator. We found this raised profile of TM issues within the corporation and we are hopeful that it will assist with physician buy in.

  
For the future, we will be:

  1. Auditing compliance post implementation of order set
  2. Implementing reflex laboratory tests once components are ordered for post transfusion testing. E.g. CBC post RBC and platelet transfusion, fibrinogen level after cryoprecipitate, etc.
  3. Auditing compliance after implementation of reflex orders.
  4. Ongoing audits to monitor progress.

   
Like all hospitals, we are not without challenges. MLTs who are core trained rotate through all departments and may only be scheduled in TM a few days a month. We ensure quality by constantly monitoring our key indicators, ensure our yearly competencies are completed and up to date and have excellent communication to keep staff informed.

  

Although staff may not feel comfortable screening transfusion orders and providing feedback to physicians, we encourage them to discuss unusual orders with the physician. Although we do not have a transfusion safety officer we connect with other hospitals within our network and work closely within our team to bring quality improvement initiatives forward and strive to encourage appropriate blood orders. We will be reporting our successes and opportunities for improvement to ORBCoN via their e-tool found on their website. We encourage all Ontario hospitals to do the same.


Archived Webcast Now Available!


The Ontario Regional Blood Coordinating Network (ORBCoN): Looking Back on 10 years of Collaboration and Networking

By: ORBCoN 
Just like in the word team, there is also no “I” in ORBCoN—although we do know individuals who pronounce it as such! In other words, the quality and volume of work that ORBCoN produces could not be accomplished without the collaboration and dedicated volunteerism of the entire “network” of transfusion stakeholders (regionally, provincially and nationally). This includes the continued support of the Ministry of Health and Long-Term Care.

  

In 2006, the three ORBCoN offices were born:

  • The Northern and Eastern Office housed at The Ottawa Hospital
  • The Central Office located at Sunnybrook Health Sciences Centre
  • The Southwest Office situated at McMaster University

  
ORBCoN’s mission, vision and values were established in a strategic planning session in 2007. Our five goals evolved from this strategy: 
   
Figure 1 ORBCoN Goals

  

For utilization improvement, ORBCoN has continually supported the proof of concept for a provincial data strategy, conducted and produced many audits and audit tools for utilization of FP, IVIG, RBC and platelets and of bedside administration of blood and specimen collection. Recommendations and guidelines for utilization and administration of these blood components/products encourage standardized progress towards best practice for appropriate and safe transfusion.

   

The educational tools and toolkits ORBCoN has produced over the past decade are numerous and support a wide variety of health professionals, patients and their families. We are particularly well known for our Bloody Easy series and the numerous provincial educational events we plan and host.

   

Following the use of inventory calculators and benchmarking and the implementation of a provincial redistribution network, hospital RBC outdate rates in Ontario have been greatly improved over the past 10 years (see figure 2).

  

Figure 2 RBC Outdate Rates in Ontario Hospitals

  

The Ontario Contingency Plan for Blood Shortages first released in 2008, helped to ensure that Ontario hospitals developed a standardized approach to blood shortage management that aligns with the National Emergency Blood Management Plan. Testing the Ontario plan through blood shortage simulation exercises helps to continually update and improve hospital plans on a provincial level.

  

For communication, ORBCoN is fortunate to have the ability to meet with our hospitals in partnership with colleagues at Canadian Blood Services (CBS) on an annual basis at our joint CBS-ORBCoN site visits. Over the past 10 years, we have built relationships with our hospital partners and developed a network that crosses regional boundaries and helps to continually improve the quality of our transfusion medicine community. Our website is a helpful communication resource that is used widely and frequently along with our regular newsletter, The ORBCoN Report. We also regularly meet with hospital peer/networking groups, our Regional Advisory, Steering and Ontario Blood Advisory Committees to stay tuned in to the current issues and challenges we face in transfusion medicine in Ontario.

  

Although quality is our foundational cornerstone, we also have initiatives contained within this goal such as our Ontario Transfusion Quality Improvement Plan and specific educators for our hospitals’ nurses and physicians.

  

In addition to partnering with CBS and hospitals, ORBCoN also forges relationships with our sister blood programs like the Ontario Transfusion Transmitted Injuries Surveillance System (ON-TTISS), Factor Concentrate Redistribution Program (FCRP) and Ontario Transfusion Coordinators (ONTraC) making us truly a provincial transfusion network.

  

Over the past decade, ORBCoN has evolved into a robust network that provides support through communication, education and networking to hospital transfusion services in the province of Ontario. We act to connect the Ministry of Health and Long-Term Care with the transfusion medicine community by identifying issues, advocating for hospital transfusion laboratories and by developing supporting resources to ensure Ontario transfusion services are complying with current standards, encouraging best practices and minimizing waste to ultimately ensure the best possible care for all patients in the province with respect to blood transfusion.


Follow Us on Twitter!


Transfusion Safety Officer Resource Manual

Emergency Blood Management Plan Revised Contact Us

 

March 2017 Newsletter


March Newsletter

The ORBCoN Report Newsletter:
Introduction to New Format 

By: Denise Evanovitch, ORBCoN Regional Manager, SW Ontario
As the world of technology evolves, ORBCoN endeavours to change with it. In the early days of ORBCoN, we issued a paper-based newsletter twice a year (The ORBCoN Report) and shipped paper copies to each of our 158 Ontario hospitals with transfusion services.

  

Later, we heard from some of our hospital contacts and our Steering Committee that we should consider being less paper based, and focus more on electronic technology. The reasons were two-fold: environmental reasons (less paper and a reduction in our carbon footprint) and many customers actually prefer an electronic format. A hospital survey demonstrated that there were no strong objections to this new format, so ORBCoN began issuing their newsletter electronically twice a year.

  

In today’s world, the rapid rate of change and the need to provide more timely information continues to accelerate. In order to meet this need and be flexible in sharing information with our hospitals, ORBCoN’s newsletter format is evolving once again. We will be issuing short articles on a monthly basis. The name of our newsletter remains the same and you can locate it on www.transfusionontario.org.

  

If you do not wish to subscribe, please select 'unsubscribe from this list' at the bottom of this newsletter. You will still be able to access our newsletter on our website even if you do not receive our reminders.

  

If there are topics of interest you would like to hear more about, feel free to contact your local ORBCoN office by email or telephone.

  
We hope you enjoy our more timely delivery of the most current transfusion information.


BE 4 Available Upcoming Events

Taking Stock: Platelets, Plugs and Pods

By: Lisa Mantifel, ORBCoN NE
Platelets are an important component of blood that help with clotting and deserve special attention. In healthy people platelets circulate and are also stored in organs such as the spleen for bleeding emergencies. Patients who experience prolonged bleeding or platelet destruction may require large quantities of platelets. Platelets can be challenging to manage due to the short shelf life and being stored at room temperature.  

  

The ORBCoN Provincial Platelet Audit project is a key activity of the provincial blood utilization strategy to improve blood management. ORBCoN launched the audit on January 9th of this year and it will run until April 7th, 2017. A web-based audit tool has been created to capture the data of the audit results by hospital sites. If your site is a part of this audit, then congratulations are in order! You are moving Ontario forward in the management of a critical blood component that is often in short supply. The goal of this audit and subsequent data analysis is to create a strategy for Ontario to ensure patients have access to platelets when they need them and that they are only transfused when appropriate.

  

The International Collaboration for Transfusion Medicine Guidelines (ICTMG) has posted a three-part podcast series titled “Platelets Unplugged: The Sticky Truth”.  The series covers the introduction of two new platelet transfusion guidelines recently published by the AABB (formerly American Association of Blood Banks) and the ICTMG. The podcast series can be accessed through the ORBCoN website in a recently added section called “Interesting Podcasts”. You can access this section under the ORBCoN Resources tab at http://transfusionontario.org/en/documents/?cat=interesting-podcasts to listen in and hear more about platelets! 


Follow Us on Twitter!


Transfusion Safety Officer Resource Manual

Emergency Blood Management Plan Revised Contact Us